欧林生物10月9日获融资买入2633.37万元，融资余额3.22亿元

Core Viewpoint - Oulin Biotech's stock has shown a positive trend with a 1.47% increase on October 9, 2023, and significant trading activity in both financing and margin trading [1] Financing Summary - On October 9, 2023, Oulin Biotech had a financing buy-in amount of 26.33 million yuan, with a net buy of 3.36 million yuan after repayments [1] - The total financing and margin trading balance reached 322 million yuan, accounting for 2.88% of the circulating market value, indicating a high level of financing activity compared to the past year [1] - The financing balance is above the 90th percentile of the past year, suggesting strong investor interest [1] Margin Trading Summary - On the same day, Oulin Biotech reported no shares were sold or repaid in margin trading, with a margin balance of 0, indicating a lack of short-selling activity [1] - The margin trading balance is also above the 80th percentile of the past year, reflecting a high level of investor confidence [1] Company Performance Summary - As of June 30, 2023, Oulin Biotech reported a total of 6,521 shareholders, an increase of 4.86% from the previous period, while the average circulating shares per person decreased by 4.63% to 62,169 shares [2] - For the first half of 2025, the company achieved a revenue of 306 million yuan, representing a year-on-year growth of 35.17%, and a net profit attributable to shareholders of 13.20 million yuan, up 147.22% year-on-year [2] Dividend Summary - Since its A-share listing, Oulin Biotech has distributed a total of 15.43 million yuan in dividends [3] Institutional Holdings Summary - As of June 30, 2025, among the top ten circulating shareholders, the fund "Xingquan Helun Mixed A" holds 15.44 million shares, unchanged from the previous period, while "Xingquan Heyi Mixed A" holds 8.92 million shares, also unchanged [3]